What is Roth Capital’s Forecast for CYCC FY2024 Earnings?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Stock analysts at Roth Capital lifted their FY2024 earnings estimates for shares of Cyclacel Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff now anticipates that the biotechnology company will post earnings of ($1.95) per share for the year, up from their previous estimate of ($2.29). Roth Capital has a “Hold” rating on the stock. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($2.29) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ Q4 2024 earnings at ($0.29) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at $3.67 EPS and FY2028 earnings at $5.49 EPS.

Separately, StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a research report on Friday. They issued a “sell” rating for the company.

Cyclacel Pharmaceuticals Price Performance

CYCC opened at $0.37 on Friday. Cyclacel Pharmaceuticals has a 12 month low of $0.35 and a 12 month high of $6.00. The stock has a market capitalization of $804,100.00, a P/E ratio of -0.04 and a beta of 0.56. The business has a 50 day simple moving average of $0.85 and a 200-day simple moving average of $1.42.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new position in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals at the end of the most recent quarter. 23.58% of the stock is currently owned by institutional investors and hedge funds.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.